Show simple item record

dc.contributor.authorEiermann, W.
dc.contributor.authorPienkowski, T.
dc.contributor.authorCrown, J.
dc.contributor.authorSadeghi, S.
dc.contributor.authorChan, Arlene
dc.contributor.authorSaleh, M.
dc.contributor.authorSehdev, S.
dc.contributor.authorProvencher, L.
dc.contributor.authorSemiglazov, V.
dc.contributor.authorPress, M.
dc.contributor.authorSauter, G.
dc.contributor.authorLindsay, M.
dc.contributor.authorRiva, A.
dc.contributor.authorBuyse, M.
dc.contributor.authorDrevot, P.
dc.contributor.authorTaupin, H.
dc.contributor.authorMackey, J.
dc.date.accessioned2017-01-30T11:21:09Z
dc.date.available2017-01-30T11:21:09Z
dc.date.created2014-11-19T01:13:19Z
dc.date.issued2011
dc.identifier.citationEiermann, W. and Pienkowski, T. and Crown, J. and Sadeghi, S. and Chan, A. and Saleh, M. and Sehdev, S. et al. 2011. Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epiderman growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. Journal of Clinical Oncology. 29 (29): pp. 3877-3884.
dc.identifier.urihttp://hdl.handle.net/20.500.11937/10830
dc.publisherAmerican Society of Clinical Oncology
dc.titlePhase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epiderman growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial
dc.typeJournal Article
dcterms.source.volume29
dcterms.source.number29
dcterms.source.startPage3877
dcterms.source.endPage3884
dcterms.source.issn0732 183X
dcterms.source.titleJournal of Clinical Oncology
curtin.accessStatusFulltext not available


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record